Core Viewpoint - On November 7, 2023, Puri Eye Hospital's stock decreased by 0.22%, with a trading volume of 27.86 million yuan, indicating a relatively stable market performance despite minor fluctuations [1] Financing Summary - On November 7, Puri Eye Hospital had a financing buy-in amount of 3.47 million yuan and a financing repayment of 3.18 million yuan, resulting in a net financing buy-in of 0.28 million yuan [1] - The total financing and securities balance as of November 7 was 72.47 million yuan, with the financing balance at 71.80 million yuan, accounting for 1.30% of the circulating market value, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The securities lending data showed a repayment of 100 shares with no shares sold, and a remaining securities lending balance of 67.53 million yuan, which is above the 60th percentile level over the past year, indicating a relatively high level of securities lending [1] Business Performance - As of September 30, 2023, Puri Eye Hospital reported a total revenue of 2.20 billion yuan for the first nine months of 2023, reflecting a year-on-year growth of 2.99% [2] - The net profit attributable to the parent company for the same period was 16.35 million yuan, showing a year-on-year increase of 3.21% [2] - The company has distributed a total of 74.51 million yuan in dividends since its A-share listing [3] Shareholder Information - As of September 30, 2023, the number of shareholders for Puri Eye Hospital was 10,400, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund held 2.40 million shares, a decrease of 192,500 shares from the previous period, while the Yuanxin Yongfeng Medical Health A Fund entered the top ten with 2.02 million shares [3]
普瑞眼科11月7日获融资买入346.76万元，融资余额7179.53万元